New tools for the cytogenetic study of leukaemia and other haematological malignancies
The Cytogenetic research line at the Josep Carreras Leukaemia Research Institute (IJC), led by Dr. Francesc Solé, has got a new analysis tool (Platform Affymetrix Microarrays').
This infrastructure, which is essential for the cytogenetic research projects of leukaemia and other haematological malignancies, has been acquired and handed over to the IJC by the José Carreras Foundation against Leukaemia, the Badalona Cancer Foundation and Caixa Tarragona.
The machine is an Affymetrix Microarray Platform which can be used to make genetic studies of the following haematological malignancies: myelodysplastic syndromes (MDS), chronic lymphocytic leukaemia, acute lymphoblastic leukaemia and multiple myeloma, among others. This technology is used for different studies, genetic markers of MDS, a study about the factors of variability in response to treatment with IMATINIB in patients with Ph + chronic myeloid leukaemia and another about the methylation in some cancers (MDS and acute myeloid leukaemia). This study will allow the diagnosis and treatment customization and improvement. Also, the expression of miRNAs in non-Hodgkin's Lymphomas (aggressive B-cell associated to the infection by HIV) will be studied to find new ways of treatment.
Dr. Francesc Solé leads this Cytogenetic research line at the Josep Carreras Leukaemia Research Institute. Dr. Solé is an eminent biologist specialized in cytogenetic diagnosis of haematological neoplasias, who joined the Josep Carreras Leukaemia Research Institute this year, on October 10th, to direct a new project focused on the study of myelodysplastic syndromes (MDS) and, at the same time, the Cytogenetic research program of the centre.
Learn more about the Josep Carreras Leukaemia Research Institute.